Pressmeddelanden, rapporter och bolagsmeddelande för Eevia Health

Orcator Oy recently purchased a significant number of shares in Eevia Health Plc through a rights issue. They acquired 5,892,334 shares and an additional 25,974,026 shares via a top guarantee commitment, without subscription rights, due to a delay in share transfer from Stein Ulve. The shares were bought at Eurocent 0.77 each, totaling EUR 45,371 and EUR 200,000 respectively. These purchases increased Orcator Oy's ownership from 4.4% to 27.4% of Eevia's outstanding shares, which now total 126,850,605. Eevia Health Plc, established in 2017, focuses on producing organic plant extracts for health-related uses and operates a facility in Finland. Orcator's increased shareholding resulted from a low subscription rate of 44.6% in the rights issue. For more details, contact Stein Ulve, CEO of Eevia Health.

Eevia Health is implementing a strategic turnaround plan to improve cash flow and meet its 2025 financial targets by reducing inventory and enhancing order income and sales revenues. Despite a rights issue that improved liquidity, the company still faces liquidity pressures and is seeking to restructure debt and extend payment timelines. Additionally, Eevia plans a directed equity issue of approximately SEK 4.5 million. CEO Stein Ulve has reorganized his share ownership and subscribed to shares in the rights issue through his company, Orcator Oy. The rights issue offered 134,111,190 shares, with a subscription rate of 44.6%. Eevia expects the shares to be registered and delivered by early March 2025. Eevia Health, founded in 2017, produces organic plant extracts from Finnish and Swedish forests, focusing on health-related products. The information was released in compliance with the EU's Market Abuse Regulation.

Eevia Health Plc has agreed to sell equipment, machines, and products to Finnish start-up Baccas Salus for 2.6 million euros, which is 1.5 million euros above their book value. The transaction requires creditor and board approvals and involves payments in cash and a seller's credit convertible into Baccas Salus shares. Eevia retains ownership until these conditions are met. Baccas Salus plans to establish a new, efficient berry manufacturing facility, while Eevia will rent the equipment for berry extract production until the new facility is operational. This deal is expected to streamline Eevia's operations and improve its balance sheet. Eevia Health, founded in 2017, specializes in organic plant extracts and operates a production facility in Finland. The company is listed on the Spotlight Stock Market in Sweden.

Stein Ulve reorganized his shareholdings by selling 2,726,717 shares in Eevia Health to Orcator Oy, a company fully owned by his spouse, for two euro cents per share. In return, he received shares in Orcator Oy, resulting in both him and his spouse each holding a 50% stake in the company. Orcator Oy, considered a Person Closely Associated, also acquired additional shares and warrants in off-market transactions, now holding 2,946,167 shares, representing 4.39% of Eevia's total shares. Orcator Oy subscribed to 5,892,334 new shares in an ongoing rights issue, investing approximately KSEK 530. It had also provided a KEUR 200 guarantee for the rights issue, potentially subscribing to 25,974,026 shares. Together with today's subscription, this accounts for 23.8% of the total offering. Including other investors' commitments, 31.8% of the rights issue is secured. Stein Ulve expressed confidence in Eevia's future, highlighting the company's strategic plan and market opportunities. Eevia Health, founded in 2017, produces organic plant extracts from wild-harvested materials, used in dietary supplements and food brands globally. The company operates a production facility in Finland and is listed on the Spotlight Stock Market in Sweden.

Stein Ulve has reorganized his shareholdings by selling 2,726,717 shares in Eevia Health to Orcator Oy, a company owned by his spouse, at two euro cents per share. In return, he received shares in Orcator Oy, giving both him and his spouse a 50% stake each in the company. Orcator Oy, now recognized as a Person Closely Associated, acquired additional shares and subscription rights, totaling 2,946,167 shares or 4.39% of Eevia's outstanding shares. Orcator Oy also subscribed to new shares in a rights issue, investing approximately KSEK 530, and has a KEUR 200 guarantee commitment, potentially subscribing to 25,974,026 shares. In total, Orcator Oy's commitments cover 23.8% of the rights issue. Stein Ulve, Eevia's CEO, expressed confidence in Eevia's future and its strategic plan. Eevia Health, founded in 2017, produces bioactive compounds from plant materials, primarily wild-harvested in Finland and Sweden, and sells them B2B globally. The company is listed on the Spotlight Stock Market in Sweden.

Eevia Health Plc, a Finnish company specializing in bioactive compounds from renewable plant materials, has partnered with an international corporation for a nutraceutical extract project. After signing a non-disclosure agreement in October 2023, they conducted a feasibility study and safety audits, confirming the ingredient's safety. Eevia has produced industrial-scale batches and is involved in a clinical study. They are now entering a Term Sheet Agreement to finalize a Purchase Agreement, which will leverage the partner's market reach and sales force, aiming for stable revenue growth. Eevia will focus on supply chain and manufacturing, while the partner handles clinical studies, marketing, and sales. This collaboration is expected to boost Eevia's growth from 2025. Eevia Health, founded in 2017, produces organically certified plant extracts, primarily from Finnish and Swedish forests, for global dietary supplement and food brands. The company is listed on the Spotlight Stock Market in Sweden.

Eevia Health Plc, a Finnish company specializing in organic plant extracts, announced sales orders totaling 54,000 euros following the BIOFACH 2025 trade fair. The orders came from Germany, Australia, and Taiwan, involving products such as Feno-Myrtillus™ 36, Fenoprolic™ Full Spectrum, and Feno-Ceraus™ 5. Eevia has the products in stock, allowing for immediate delivery, which positively impacts cash flow. These are repeat orders, with expectations for future orders from the same customers. Eevia, established in 2017, focuses on sustainable bioactive compounds for health, operating a green-chemistry facility in Finland. It is publicly listed on the Spotlight Stock Market in Sweden.

BIOFACH is a major trade fair for organic food held annually in Nuremberg, Germany, attracting exhibitors and visitors from the organic and natural sectors. The 2024 event featured 2,561 exhibitors and 34,626 visitors from 128 countries. Eevia Health Plc plans to participate in the 2025 BIOFACH tradeshow, promoting its organic products with its distribution partner in the DACH region, BREKO. Eevia Health, founded in 2017, produces bioactive compounds from renewable plant materials, focusing on gut and related health. The company operates a green-chemistry production facility in Finland and markets its extracts globally. Eevia Health is listed on the Spotlight Stock Market in Sweden under the ticker EEVIA. For more information, contact CEO Stein Ulve or visit their website.

Eevia har genomfört lagstadgade YT-förhandlingar och går från 19 anställda till 9. Två personer avgår frivilligt, fyra får nya anställningar i samband med att tillgångar avyttras, två går ner på deltid och fyra anställningar avslutas. Bolaget beräknar spara cirka 490 000 euro i årliga personalkostnader. Förändringarna träder i kraft i februari 2025 och väntas påverka kostnader positivt redan under första kvartalet 2024. Trots neddragningarna behåller Eevia tillräcklig kapacitet för att leverera sitt intäktsmål på 3 miljoner euro för 2025. Strategin inriktas nu på proantocyanidin-baserade lösningar för tarmhälsa, vilket kräver ökad kompetens inom försäljning, marknadsföring och produktutveckling. Viss nyrekrytering förväntas balansera kostnadsbesparingarna. Syftet med omstruktureringen är att återställa lönsamheten och möjliggöra fortsatt tillväxt inom vetenskapligt baserade växtextrakt. Eevia är listat på Spotlight Stock Market i Sverige och producerar ekologiska plantbaserade ingredienser som säljs globalt för användning i kosttillskott och livsmedel.

Eevia har avslutat de lagstadgade samarbetsförhandlingarna i Finland, vilket påverkar företagets personalstyrka som uppgår till 19 personer. Tre anställda lämnar företaget frivilligt, fyra övergår till nya arbetsgivare i samband med att vissa tillgångar avyttras, två går ner till deltidsanställning och fyra anställningar avslutas helt. Kvar blir nio personer, vilket företaget anser vara tillräckligt för att behålla nödvändig kompetens och nå målet om en omsättning på 3 miljoner euro under 2025. Förändringarna träder i kraft i februari 2025 och väntas ge årliga lönekostnadsbesparingar på 490 000 euro. Dessa kostnadsförändringar påverkar resultatet redan från första kvartalet 2024. Samtidigt planerar Eevia att utöka resurserna inom försäljning, marknadsföring och produktledning för att möta den nya strategin, som fokuserar på proantocyanidinbaserade lösningar för maghälsa. Vissa nyrekryteringar kommer att kunna kompensera för delar av de besparingar som personalneddragningen innebär. Åtgärderna syftar till att återställa lönsamheten och anpassa organisationen till framtida behov. Eevia fortsätter därmed att satsa på vetenskapligt baserade växtextrakt med fokus på mag- och närliggande hälsa, samtidigt som företaget upprätthåller en lägre och mer flexibel kostnadsstruktur. Eevia Health Plc är noterat på Spotlight Stock Market sedan juni 2021 och levererar ekologiskt certifierade extrakt från vilda växter i norra Finland och Sverige.